换一批摘要MicroRNAs (miRNAs) are a class of highly abundant non-coding RNA molecules that are involved in several biological processes. Many miRNAs are often deregulated in several diseases including cancer. There is substantial interest in exploiting miRNAs for therapeutic applications. In this editorial, we briefly review current advances in the use of miRNAs or antisense oligonucleotides (antagomirs) for such therapies. One of the key issues related to therapy using miRNAs is degradation of naked particles in vivo. To overcome this limitation, delivery systems for miRNA-based therapeutic agents have been developed, which hold tremendous potential for improving therapeutic outcome of cancer patients.
更多相关知识
分类号
R730.2（肿瘤学一般性问题）
栏目名称
发布时间
2011-08-18（万方平台首次上网日期，不代表论文的发表时间）
基金项目
Rajesha Rupaimoole is supported by the Hawkins Biomarker Discovery fellowship.Portions of this research were supported by grants from the National Institutes of Health （(CA109298, CA110793, CA128797,RC2GM092599, U54 CA151668)）
Department of Defense（(OC073399,OC093146,BC085265)）
a Program Project Development Grant from the Ovarian Cancer Research Fund,Inc,the Ward Family,the Zarrow Foundation,the Marcus Foundation,the M.D.Anderson Cancer Center SPORE in Ovarian Cancer（(P50 CA083639)）
Uterine Cancer（(P50 CA098258)）
the Laura and John Arnold Foundation,and the Betty Ann Asche Murray Distinguished Professorship
- 浏览135
- 被引13
- 下载1
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
